GRAIL (NASDAQ:GRAL) Stock Price Target Raised at Piper Sandler

GRAIL (NASDAQ:GRAL) had its price target boosted by Piper Sandler from $74.00 to $130.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Piper Sandler‘s target price would indicate a potential upside of 1.50% from the company’s previous close.

GRAL has been the subject of a number of other reports. Wall Street Zen raised shares of GRAIL from a “sell” rating to a “hold” rating in a report on Sunday, September 13th. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a report on Thursday, October 15th. Canaccord Genuity Group upped their price objective on shares of GRAIL from $80.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 28th. Mizuho increased their target price on shares of GRAIL from $65.00 to $100.00 and gave the company a “neutral” rating in a research note on Friday, September 25th. Finally, UBS Group lifted their target price on GRAIL from $105.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, October 2nd. Five research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $128.80.

GRAIL Price Performance

GRAL opened at $128.08 on Tuesday. The business has a 50 day moving average of $118.11 and a 200-day moving average of $79.46. GRAIL has a 1-year low of $41.50 and a 1-year high of $166.48.

GRAIL (NASDAQ:GRAL) last announced its earnings results on Wednesday, November 4th. The company reported ($2.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.45) by $0.24. The business had revenue of $37.53 million for the quarter, compared to analyst estimates of $44.21 million. GRAIL had a negative net margin of 243.80% and a negative return on equity of 15.99%. Equities research analysts predict that GRAIL will post -10.07 earnings per share for the current fiscal year.

Insider Buying and Selling at GRAIL

In other GRAIL news, CFO Aaron Freidin sold 23,619 shares of the business’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $146.39, for a total value of $3,457,585.41. Following the sale, the chief financial officer owned 225,364 shares of the company’s stock, valued at $32,991,035.96. The trade was a 9.49% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Andrew Partridge sold 7,873 shares of the stock in a transaction on Monday, October 5th. The shares were sold at an average price of $146.39, for a total transaction of $1,152,528.47. Following the completion of the transaction, the insider owned 155,865 shares of the company’s stock, valued at approximately $22,817,077.35. This represents a 4.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 129,944 shares of company stock valued at $14,832,805 in the last 90 days. 1.83% of the stock is currently owned by company insiders.

Institutional Trading of GRAIL

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GRAL. BlackRock Inc. raised its position in GRAIL by 20.5% in the second quarter. BlackRock Inc. now owns 3,577,075 shares of the company’s stock worth $244,207,000 after purchasing an additional 608,539 shares in the last quarter. State Street Corp boosted its holdings in GRAIL by 26.1% during the second quarter. State Street Corp now owns 2,385,514 shares of the company’s stock valued at $162,859,000 after purchasing an additional 493,621 shares in the last quarter. Primecap Management Co. CA acquired a new stake in GRAIL during the second quarter valued at approximately $148,836,000. Bank of America Corp DE boosted its holdings in GRAIL by 29.0% during the first quarter. Bank of America Corp DE now owns 914,114 shares of the company’s stock valued at $47,241,000 after purchasing an additional 205,611 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of GRAIL by 88.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 408,650 shares of the company’s stock valued at $21,104,000 after purchasing an additional 191,857 shares during the period.

GRAIL Company Profile

GRAIL, Inc is a healthcare company developing blood-based tests for the early detection of multiple cancers. Its approach analyzes patterns in cell-free DNA, including DNA methylation signals, to help identify a possible cancer signal and predict its origin in the body.

GRAIL’s flagship product is Galleri, a multi-cancer early detection test intended for use alongside—not as a replacement for—recommended cancer screening. The company also conducts clinical research to evaluate the test and advance its early-detection technology.

Founded in 2016 as a spinout of Illumina, GRAIL became part of Illumina in 2021 and returned to independent operation in 2024.